Related Experiment Video
Updated: Oct 10, 2025
05:22
Iris Fixation via External Pentagram Suturing
Published on: May 5, 2022
1.5K
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy
Summary
Erdafitinib, a FGFR inhibitor for urothelial carcinoma, can cause central serous chorioretinopathy. Dose adjustment or discontinuation may be needed to manage this vision-threatening side effect.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Erdafitinib is an FDA-approved fibroblast growth factor receptor (FGFR) inhibitor for advanced urothelial carcinoma.
- Central serous chorioretinopathy (CSCR) is an ocular adverse effect associated with erdafitinib treatment.
Observation:
- A case study details an 80-year-old patient with urothelial cancer who developed CSCR on 8 mg daily erdafitinib.
- The CSCR resolved upon erdafitinib discontinuation and recurred with re-challenge at a reduced dose (6 mg daily).
Findings:
- Erdafitinib-induced CSCR affects approximately 25% of patients at the 8-mg dose.
- While dose interruption or reduction can resolve mild to moderate CSCR, complete discontinuation may be necessary in some cases.
Implications:
- Increased awareness of erdafitinib-induced CSCR is crucial for early detection and management.
- Close collaboration between oncologists and ophthalmologists is essential for managing ocular adverse events and optimizing patient outcomes.
- Adherence to erdafitinib dose management guidelines is vital to mitigate visual consequences.
